{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:48:32Z","timestamp":1782730112844,"version":"3.54.5"},"reference-count":53,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Stichting AutoImmuun Onderzoek"},{"DOI":"10.13039\/501100008359","name":"Maag Lever Darm Stichting","doi-asserted-by":"crossref","award":["(I16-09)"],"award-info":[{"award-number":["(I16-09)"]}],"id":[{"id":"10.13039\/501100008359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The interaction between the gut microbiota and the host immune system is implicated in the pathogenesis of inflammatory bowel disease, including ulcerative colitis (UC). Targeting the gut microbiota with faecal microbiota transplantation (FMT) from a healthy donor has shown promise in inducing remission in patients with active UC. However, mixed results and protocol heterogeneity have limited its practical application. Our previous Transfer of Faeces in Ulcerative Colitis; Restoring Homeostasis (TURN) trial found a correlation of clinical response with specific strains and butyrate production. Since most gut microbes, including many butyrate producers, are anaerobes, anoxic processing of donor stool may be essential to increase efficacy of FMT in UC. This trial aims to enhance FMT efficacy by applying strict anoxic processing, selecting donors based on microbial composition and using repetitive dual-route administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This randomised, double-blind, placebo-controlled, multicentre study evaluates the efficacy of strictly anoxic prepared donor FMT compared with anoxic prepared autologous FMT in patients with mild to moderate active UC. An open-label extension option is available for non-responders in the autologous arm. Included patients will receive 4\u2009weekly FMTs, comprising two double-route administrations (nasoduodenal administration combined with enema) and two single enemas. Donors are selected based on their microbiota profile, informed by our previous TURN trial and literature. A total of 76 patients evaluable for the primary endpoint will be included. The primary endpoint is steroid-free clinical and endoscopic remission at week 8, assessed by the adapted Mayo score. An interim analysis will be conducted midway through the study by a Data Safety Monitoring Board to monitor efficacy and safety. Other outcomes of this study include the evaluation of clinical, endoscopic and histological response. In addition to clinical results, this study aims to provide valuable insights into specific microbial strains, metabolites and mechanisms correlated with response, aiding in the development of future microbial therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained from the medical ethics committee of the Amsterdam University Medical Centre in the Netherlands (reference number 2018_057). All participants will provide written informed consent. The results of the trial will be disseminated through publication in a peer-reviewed journal and presentations at (inter)national conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      Prospectively registered in May 2018 in the Dutch Trial Register (NTR\/LTR) as NL7770. Assigned NL-OMON52507 following the transition of the Dutch Trial Register to the Overview of Medical Research in the Netherlands. Also registered at ClinicalTrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05998213\">NCT05998213<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-107097","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:52:58Z","timestamp":1778035978000},"page":"e107097","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Transfer of faeces in ulcerative colitis 2: improving efficacy \u2013 study protocol for a multicentre randomised controlled trial (TURN2 study)"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05998213","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05998213","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-044X","authenticated-orcid":false,"given":"M\u00e8lanie V","family":"B\u00e9nard","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam JW","family":"Van Der Spek","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Davids","sequence":"additional","affiliation":[{"name":"Microbiota Center Amsterdam (MiCA), Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands"},{"name":"Department of Experimental Vascular Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin G","family":"Zoetendal","sequence":"additional","affiliation":[{"name":"Laboratory of Microbiology, Wageningen University & Research, Wageningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Rethans","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florine H","family":"Zwezerijnen-Jiwa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands"},{"name":"Amsterdam Gastroenterology Endocrinology and Metabolism, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn C","family":"Visschedijk","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinse K","family":"Weersma","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel Y","family":"Ponsioen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026062608310480000_16.5.e107097.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00966-2"},{"key":"2026062608310480000_16.5.e107097.2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study","volume":"5","author":"Burisch","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062608310480000_16.5.e107097.3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062608310480000_16.5.e107097.4","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2018.1545574"},{"key":"2026062608310480000_16.5.e107097.5","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9050977","article-title":"Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease","volume":"9","author":"Aldars-Garc\u00eda","year":"2021","journal-title":"Microorganisms"},{"key":"2026062608310480000_16.5.e107097.6","doi-asserted-by":"publisher","DOI":"10.1053\/J.GASTRO.2019.11.294"},{"key":"2026062608310480000_16.5.e107097.7","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14201"},{"key":"2026062608310480000_16.5.e107097.8","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-013-0337-1","article-title":"Fecal microbiota transplantation: indications, methods, evidence, and future directions","volume":"15","author":"Borody","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"2026062608310480000_16.5.e107097.9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.045"},{"key":"2026062608310480000_16.5.e107097.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.20046"},{"key":"2026062608310480000_16.5.e107097.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30182-4"},{"key":"2026062608310480000_16.5.e107097.12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.001"},{"key":"2026062608310480000_16.5.e107097.13","doi-asserted-by":"publisher","DOI":"10.1038\/ismej.2017.44"},{"key":"2026062608310480000_16.5.e107097.14","doi-asserted-by":"crossref","DOI":"10.3390\/nu15102275","article-title":"Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review","volume":"15","author":"Recharla","year":"2023","journal-title":"Nutrients"},{"key":"2026062608310480000_16.5.e107097.15","doi-asserted-by":"crossref","DOI":"10.3390\/nu15092211","article-title":"Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota","volume":"15","author":"Fusco","year":"2023","journal-title":"Nutrients"},{"key":"2026062608310480000_16.5.e107097.16","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2016.1186334"},{"key":"2026062608310480000_16.5.e107097.17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110591"},{"key":"2026062608310480000_16.5.e107097.18","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11092238","article-title":"Anaerobic Feces Processing for Fecal Microbiota Transplantation Improves Viability of Obligate Anaerobes","volume":"11","author":"B\u00e9nard","year":"2023","journal-title":"Microorganisms"},{"key":"2026062608310480000_16.5.e107097.19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jhin.2018.07.037","article-title":"The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines","volume":"100","author":"Mullish","year":"2018","journal-title":"Journal of Hospital Infection"},{"key":"2026062608310480000_16.5.e107097.20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-329948"},{"key":"2026062608310480000_16.5.e107097.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.18098"},{"key":"2026062608310480000_16.5.e107097.22","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091339"},{"key":"2026062608310480000_16.5.e107097.23","unstructured":"NDFB . Protocol screening feces donor: netherlands donor feces bank. 2016. Available: https:\/\/www.ndfb.nl\/uploads\/7\/2\/9\/7\/72970627\/160125_screening_protocol_feces_donor_versie_3.pdf"},{"key":"2026062608310480000_16.5.e107097.24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319548"},{"key":"2026062608310480000_16.5.e107097.25","unstructured":"FDA . Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms: us food and drug administration. 2019. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse"},{"key":"2026062608310480000_16.5.e107097.26","unstructured":"FDA . Fecal microbiota for transplantation: new safety information - regarding additional protections for screening donors for covid-19 and exposure to sars-cov-2 and testing for sars-cov-2: us food and drug administration. 2020. Available: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fecal-microbiota-transplantation-new-safety-information-regarding-additional-protections-screening"},{"key":"2026062608310480000_16.5.e107097.27","unstructured":"FDA . Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to monkeypox virus: us food and drug administration. 2022. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections-0"},{"key":"2026062608310480000_16.5.e107097.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276323","article-title":"Challenges and costs of donor screening for fecal microbiota transplantations","volume":"17","author":"B\u00e9nard","year":"2022","journal-title":"PLoS ONE"},{"key":"2026062608310480000_16.5.e107097.29","doi-asserted-by":"crossref","DOI":"10.1038\/s43705-021-00065-5","article-title":"In vitro metabolic capacity of carbohydrate degradation by intestinal microbiota of adults and pre-frail elderly","volume":"1","author":"An","year":"2021","journal-title":"ISME Commun"},{"key":"2026062608310480000_16.5.e107097.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172892"},{"key":"2026062608310480000_16.5.e107097.31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.06.031"},{"key":"2026062608310480000_16.5.e107097.32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310187"},{"key":"2026062608310480000_16.5.e107097.33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312722"},{"key":"2026062608310480000_16.5.e107097.34","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1053\/j.gastro.2021.02.035","article-title":"An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials","volume":"160","author":"Ma","year":"2021","journal-title":"Gastroenterology"},{"key":"2026062608310480000_16.5.e107097.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082300","article-title":"High-Throughput Multi-Analyte Luminex Profiling Implicates Eotaxin-1 in Ulcerative Colitis","volume":"8","author":"Coburn","year":"2013","journal-title":"PLoS ONE"},{"key":"2026062608310480000_16.5.e107097.36","doi-asserted-by":"crossref","DOI":"10.3390\/nu11112739","article-title":"Nutritional Assessment in Inflammatory Bowel Disease (IBD)-Development of the Groningen IBD Nutritional Questionnaires (GINQ)","volume":"11","author":"Peters","year":"2019","journal-title":"Nutrients"},{"key":"2026062608310480000_16.5.e107097.37","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2026062608310480000_16.5.e107097.38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04871.x"},{"key":"2026062608310480000_16.5.e107097.39","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/ecco-jcc\/jjad114","article-title":"Inflammatory Bowel Disease Is not Linked to a Higher Rate of Adverse Events in Colonoscopy-a Nationwide Population-based Study in Sweden","volume":"17","author":"Alexandersson","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026062608310480000_16.5.e107097.40","doi-asserted-by":"publisher","DOI":"10.4037\/ajcc2017369"},{"key":"2026062608310480000_16.5.e107097.41","doi-asserted-by":"crossref","DOI":"10.1590\/1518-8345.3355.3400","article-title":"Nasogastric\/nasoenteric tube-related adverse events: an integrative review","volume":"29","author":"Motta","year":"2021","journal-title":"Rev Lat Am Enfermagem"},{"key":"2026062608310480000_16.5.e107097.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161174","article-title":"Systematic Review: Adverse Events of Fecal Microbiota Transplantation","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS ONE"},{"key":"2026062608310480000_16.5.e107097.43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2024.05.017","article-title":"Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility","volume":"23","author":"Caenepeel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062608310480000_16.5.e107097.44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2468-1253(21)00400-3","article-title":"Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Haifer","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026062608310480000_16.5.e107097.45","doi-asserted-by":"crossref","first-page":"14494","DOI":"10.1038\/s41598-023-41182-6","article-title":"Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis","volume":"13","author":"Feng","year":"2023","journal-title":"Sci Rep"},{"key":"2026062608310480000_16.5.e107097.46","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/ibd\/izac135","article-title":"Efficacy of Fecal Microbiota Transplantation in the Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials","volume":"29","author":"El Hage Chehade","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026062608310480000_16.5.e107097.47","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cgh.2024.10.001","article-title":"Gut Microbiota Features in Relation to Fecal Microbiota Transplantation Outcome in Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"23","author":"B\u00e9nard","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026062608310480000_16.5.e107097.48","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15116"},{"key":"2026062608310480000_16.5.e107097.49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104088","article-title":"Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis","volume":"81","author":"Rees","year":"2022","journal-title":"EBioMedicine"},{"key":"2026062608310480000_16.5.e107097.50","doi-asserted-by":"crossref","unstructured":"Haifer C , Luu LDW , Paramsothy S , et al . Microbial determinants of effective donors in faecal microbiota transplantation for UC. Gut 2022. doi:10.1136\/gutjnl-2022-327742","DOI":"10.1136\/gutjnl-2022-327742"},{"key":"2026062608310480000_16.5.e107097.51","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv203"},{"key":"2026062608310480000_16.5.e107097.52","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015276","article-title":"Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme","volume":"7","author":"Walters","year":"2017","journal-title":"BMJ Open"},{"key":"2026062608310480000_16.5.e107097.53","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14011","article-title":"Investigator initiated research in times of COVID-19: Let\u2019s go digital!","volume":"32","author":"Schuitenmaker","year":"2020","journal-title":"Neurogastroenterol Motil"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-107097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:28:04Z","timestamp":1782728884000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-107097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-107097"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-107097","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}